0001193125-19-004169.txt : 20190108 0001193125-19-004169.hdr.sgml : 20190108 20190108060705 ACCESSION NUMBER: 0001193125-19-004169 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190108 FILED AS OF DATE: 20190108 DATE AS OF CHANGE: 20190108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TAKEDA PHARMACEUTICAL CO LTD CENTRAL INDEX KEY: 0001395064 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38757 FILM NUMBER: 19514619 BUSINESS ADDRESS: STREET 1: 1-1, DOSCHOMACHI 4-CHOME CITY: CHUO-KU, OSALCA 540-8645 STATE: M0 ZIP: 00000 MAIL ADDRESS: STREET 1: 1-1, DOSCHOMACHI 4-CHOME CITY: CHUO-KU, OSALCA 540-8645 STATE: M0 ZIP: 00000 6-K 1 d687446d6k.htm FORM 6-K Form 6-K
Table of Contents

 

 

FORM 6-K

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

Commission File Number: 001-38757

For the month of January 2019

 

 

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(Translation of registrant’s name into English)

 

 

1-1, Nihonbashi-Honcho 2-Chome

Chuo-ku, Tokyo 103-8668

Japan

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


Table of Contents


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    TAKEDA PHARMACEUTICAL COMPANY LIMITED
Date: January 8, 2019     By:  

/s/ Mitsuhiro Okada

      Mitsuhiro Okada
      Head of Global Treasury & Finance Management


Table of Contents
LOGO    Better Health, Brighter Future

News Release

Notice regarding the Acquisition of the Entire Issued and To Be Issued

Share of Shire plc. by Takeda Pharmaceutical Company Limited

Osaka, Japan - January 8, 2019 – Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) confirms that the scheme of arrangement (the “Scheme of Arrangement”) in relation to the proposed acquisition (the “Acquisition”) of Shire plc (“Shire”) by Takeda, as announced in the “Agreement on Commencement of a Friendly Acquisition Procedure to Make Shire plc a Wholly-owned Subsidiary” on May 8, 2018, became effective in accordance with its terms on January 8, 2019 (the “Effective Date”) and the entire issued and to be issued share capital of Shire is now owned by Takeda.

As a result of the Scheme having become effective, all of the conditions to the issuance of Takeda’s new shares (the “New Takeda Shares”) as part of the consideration for the Acquisition, as approved at Takeda’s Extraordinary Shareholders Meeting held on December 5, 2018, have been satisfied. Accordingly, the New Takeda Shares will be issued on the Effective Date in accordance with the subscription requirements announced in the “Notice regarding the determination of subscription requirements to issue new Takeda Shares” on January 7, 2019.

End of Document

GRAPHIC 2 g687446img001.jpg GRAPHIC begin 644 g687446img001.jpg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